Onychomycosis Pipeline Insight
DelveInsight’s,“Onychomycosis – Pipeline Insights, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Onychomycosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Onychomycosis, traditionally referred to a nondermatophytic infection of the nail but is now used as a general term to denote any fungal nail infection (tinea unguium specifically describes a dermatophytic invasion of the nail plate). In spite of the clearly diseased appearance associated with this condition, onychomycosis is all too often regarded as merely a cosmetic problem of relatively minor importance that is hardly worth the effort to resolve. This belief may have been supported by the adverse effects and long dosing courses associated with some of the earlier antifungal agents.
Onychomycosis in immunocompromised patients, such as those infected with human immunodeficiency virus (HIV), can pose a more serious health problem.
Nails have asymptomatic patches of white or yellow discoloration and deformity. There are 3 common characteristic patterns:
- Distal subungual: The nails thicken and yellow, keratin and debris accumulate distally and underneath, and the nail separates from the nail bed (onycholysis).
- Proximal subungual: A form that starts proximally and is a marker of immunosuppression.
- White superficial: A chalky white scale slowly spreads beneath the nail surface.
Diagnosis of onychomycosis can often be made by visual inspection alone; laboratory tests may not be needed, but include:
- Microscopy: Potassium hydroxide (KOH) stain is a commonly-used method because it is inexpensive and easy to perform. Nail clippings or scrapings are placed in a drop of KOH and examined under a microscope for the presence of fungal elements. 3 Periodic Acid-Schiff (PAS) staining can also be used.
- Culture: Fungal culture on Sabouraud’s medium or dermatophyte test medium (DTM) can be used to identify the infecting organism.
Fungal nail infections can be difficult to cure, and they typically don’t go away without antifungal treatment. The best treatment for a fungal nail infection is usually prescription antifungal pills taken by mouth. In severe cases, a doctor might remove the nail completely.
It can take several months to a year for the infection to go away. Topical antifungal agents can be used but are often ineffective. Oral terbinafine is considered to be the first-line treatment for confirmed onychomycosis; the treatment course is generally 6 weeks for fingernails and 12 weeks for toenails. Azoles can also be used. Surgical debridement or removal of the affected nail is also a consideration for cases that are resistant to antifungals, and laser treatments for onychomycosis appear to be a promising area for future study.
Onychomycosis Emerging Drugs Chapters
This segment of the Onychomycosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Onychomycosis Emerging Drugs
Moberg Pharma is conducting a multi-centre, randomized, two-armed, parallel group and evaluator-blinded study of efficacy and safety of topical MOB015B in the treatment of mild to moderate Distal Subungual Onychomycosis (DSO). The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.
Further product details are provided in the report……..
Onychomycosis: Therapeutic Assessment
This segment of the report provides insights about the different Onychomycosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Onychomycosis
There are approx. 5+ key companies which are developing the therapies for Onychomycosis. The companies which have their Onychomycosis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Blueberry Therapeutics, Moberg Pharma AB etc.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Onychomycosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Proteins and peptides
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Onychomycosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Onychomycosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Onychomycosis drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Onychomycosis R&D. The therapies under development are focused on novel approaches to treat/improve Onychomycosis.
Onychomycosis Report Insights
- Onychomycosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Onychomycosis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Onychomycosis drugs?
- How many Onychomycosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Onychomycosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Onychomycosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Onychomycosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Blueberry Therapeutics
- IQVIA Biotech
- Moberg Pharma AB